The Pharma Data

AUGUST 16, 2021

Better activation of innate and adaptive immune responses was achieved with CV2CoV, resulting in faster response onset, higher titers of antibodies, and stronger memory B and T cell activation as compared to the first-generation candidate, CVnCoV.

Immune Response 52

Immune Response Vaccine Virus RNA 52

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. They used an engineered adeno-associated virus (AAV) that crosses the blood-brain barrier after intravenous administration. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142

Disease Therapies Engineering Clinical Trials 142

Drug Discovery World

NOVEMBER 8, 2023

Helmut Salih, MD, Professor for Translational Immunology, Medical Director, Clinical Collaboration Unit Translational Immunology, University Hospital Tuebingen and DKFZ Heidelberg, Germany; Co-Founder, TWYCE GmbH, on: ‘An optimised IgG-Based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers’.

Engineering 162

Engineering Protein Expression Therapies Science 162

The Pharma Data

OCTOBER 26, 2020

The treatment induced HPV-specific T-cell responses and was associated with increased levels of immune cell infiltration in the tumors and expression of genes associated with activation of the immune system. An overall response rate of 23.5% 27, 2020 06:30 UTC.

Vaccine 52

Vaccine Virus Trials Treatment 52

Codon

APRIL 9, 2023

Of those, 17 children responded to the treatment, and the 3-year overall survival rate was 60 percent. AI + Bio *Transfer learning for cross-context prediction of protein expression from 5’UTR sequence. The CAR-T cells were detectable in 26 out of 27 children after 30 months. Subscribe to learn more. McGrady N.R.

Therapies 52

Therapies RNA Engineering Vaccine 52